Search research articles
Contact Us
Filters
Showing results (1-10 of 202) with videos related to
Page
of 21
Sort By:
Immunological Reviews
|
August 30, 2024
Nanobody-based heavy chain antibodies and chimeric antibodies
Friedrich Koch-Nolte
The FEBS Journal
|
June 19, 2013
Physiology of ADP-ribosylation
Friedrich Koch-Nolte, Mathias Ziegler
Frontiers in Immunology
|
November 22, 2018
Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
Peter Bannas, Friedrich Koch-Nolte
Frontiers in Immunology
|
December 8, 2017
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
Peter Bannas, Julia Hambach, Friedrich Koch-Nolte
Nucleic Acids Research
|
September 23, 2006
ZBP1 subcellular localization and association with stress granules is controlled by its Z-DNA binding domains
Nikolaus Deigendesch, Friedrich Koch-Nolte, Stefan Rothenburg
Annual Review of Immunology
|
January 25, 2019
Purine Release, Metabolism, and Signaling in the Inflammatory Response
Joel Linden, Friedrich Koch-Nolte, Gerhard Dahl
Frontiers in Cellular Neuroscience
|
November 7, 2014
Nanobodies as modulators of inflammation: potential applications for acute brain injury
Björn Rissiek, Friedrich Koch-Nolte, Tim Magnus
Frontiers in Pharmacology
|
April 12, 2018
Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity
Stephan Menzel, Nicole Schwarz, Friedrich Haag, et al.
Current Medicinal Chemistry
|
April 14, 2004
Ecto-ADP-ribosyltransferases (ARTs): emerging actors in cell communication and signaling
Michel Seman, Sahil Adriouch, Friedrich Haag, et al.
Annals of the New York Academy of Sciences
|
March 23, 2004
T-cell survival regulator LKLF is not involved in inappropriate apoptosis of diabetes-prone BBDP rat T cells
Philip Diessenbacher, Katrin Bartels, Friedrich Koch-Nolte, et al.
Page
of 21
Search research articles
Search
Showing results (1-10 of 202) with videos related to
Sort By:
Page
of 21
Immunological Reviews
|
August 30, 2024
Nanobody-based heavy chain antibodies and chimeric antibodies
Friedrich Koch-Nolte
The FEBS Journal
|
June 19, 2013
Physiology of ADP-ribosylation
Friedrich Koch-Nolte, Mathias Ziegler
Frontiers in Immunology
|
November 22, 2018
Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
Peter Bannas, Friedrich Koch-Nolte
Frontiers in Immunology
|
December 8, 2017
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
Peter Bannas, Julia Hambach, Friedrich Koch-Nolte
Nucleic Acids Research
|
September 23, 2006
ZBP1 subcellular localization and association with stress granules is controlled by its Z-DNA binding domains
Nikolaus Deigendesch, Friedrich Koch-Nolte, Stefan Rothenburg
Annual Review of Immunology
|
January 25, 2019
Purine Release, Metabolism, and Signaling in the Inflammatory Response
Joel Linden, Friedrich Koch-Nolte, Gerhard Dahl
Frontiers in Cellular Neuroscience
|
November 7, 2014
Nanobodies as modulators of inflammation: potential applications for acute brain injury
Björn Rissiek, Friedrich Koch-Nolte, Tim Magnus
Frontiers in Pharmacology
|
April 12, 2018
Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity
Stephan Menzel, Nicole Schwarz, Friedrich Haag, et al.
Current Medicinal Chemistry
|
April 14, 2004
Ecto-ADP-ribosyltransferases (ARTs): emerging actors in cell communication and signaling
Michel Seman, Sahil Adriouch, Friedrich Haag, et al.
Annals of the New York Academy of Sciences
|
March 23, 2004
T-cell survival regulator LKLF is not involved in inappropriate apoptosis of diabetes-prone BBDP rat T cells
Philip Diessenbacher, Katrin Bartels, Friedrich Koch-Nolte, et al.
Page
of 21